UK MHRA authorised orforglipron tablet on 10 August 2026, first in Europe
On 10 August 2026 the MHRA authorised orforglipron (Foundayo) for weight management and type 2 diabetes, for adults with a BMI of 30 or above, or 27 to 30 with at least one weight-related comorbidity.


